Birdie, a London-based health tech startup focusing on transforming the state of elderly care, has raised $30m (£24.5m) in a Series B funding round.
Founded in 2017, Birdie is aiming to reinvent home healthcare and support older generations with an all-in-one software solution.
Birdie’s services include scheduling visits, creating care plans, preparing audit reports, invoicing, as well as full-service care management.
“Our vision has always been to create a world where everyone can age with confidence at home,” said Birdie co-founder and CEO Max Parmentier.
“In five years, we have become the operating system for care providers, building the largest home healthcare dataset for the elderly in Europe. With millions of clinical data points collected each month, we plan on deriving personalised and predictive insights to enable a value-based healthcare delivery model.
“This latest investment, just over one year from the last round, is not only a validation of Birdie’s growth trajectory but also an endorsement of the potential of our social impact.”
The Series B round was led by investment firm Sofina, with participation from OMERS Ventures and follow-on investment from Index Ventures.
“The home healthcare tech sector seems ripe for an innovative leader like Birdie to catalyse the necessary social change,” said Harold Boël, CEO of Sofina.
“Aligned with our strategy to back growing and sustainable businesses, we’re excited to join them on their mission to enrich the lives of millions of older adults through preventive and personalised care at home.”
Stéphane Kurgan, venture partner at Index Ventures, added: “What really sets Birdie apart is the combination of an intuitive product experience coupled with a true partnership approach to digital transformation.”
The latest investment has brought the total amount of funding raised by Birdie to $52m (£42.6m).
The company’s last funding round was in May 2021, when Birdie raised £8.2m from Index Ventures and Kamet Ventures.
Birdie also had a £6m fundraise in November 2018 led by AXA.